 | • レポートコード：MRC-IM30110 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、140ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| グローバル調査会社のIMARC社は、2021年107億ドルであった世界の前立腺肥大症治療市場規模が2027年には149億ドルに達し、予測期間中、年平均5.7％成長すると予測しています。本調査レポートでは、前立腺肥大症治療の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、治療種類別（医薬品、低侵襲手術、レーザー治療、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目を掲載しています。また、こちらの調査レポートに掲載されている企業情報には、Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A.などが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の前立腺肥大症治療市場規模：治療種類別 - 医薬品における市場規模 - 低侵襲手術における市場規模 - レーザー治療における市場規模 - その他前立腺肥大症治療の市場規模 ・世界の前立腺肥大症治療市場規模：地域別 - 北米の前立腺肥大症治療市場規模 - アジアの前立腺肥大症治療市場規模 - 欧州の前立腺肥大症治療市場規模 - 中南米の前立腺肥大症治療市場規模 - 中東・アフリカの前立腺肥大症治療市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global benign prostatic hyperplasia treatment market size reached US$ 10.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 14.9 Billion by 2027, exhibiting a growth rate (CAGR) of 5.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.
The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on treatment type.
Breakup by Treatment Type:
Drug Class
Alpha-Blockers
5-Alpha-reductase Inhibitors (5-ARIs)
Phosphodiesterase-5 Enzyme Inhibitors
Others
Minimally Invasive Surgeries
Transurethral Resection of the Prostate (TURP)
Transurethral Incision of the Prostate (TUIP)
Transurethral Microwave Thermotherapy (TUMT)
Robotic Surgeries
Prostatic Urethral Lifts
Others
Laser Therapy
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Benign Prostatic Hyperplasia Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Drug Class
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Alpha-Blockers
6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
6.1.2.4 Others
6.1.3 Market Forecast
6.2 Minimally Invasive Surgeries
6.2.1 Market Trends
6.2.2 Major Types
6.2.2.1 Transurethral Resection of the Prostate (TURP)
6.2.2.2 Transurethral Incision of the Prostate (TUIP)
6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
6.2.2.4 Robotic Surgeries
6.2.2.5 Prostatic Urethral Lifts
6.2.2.6 Others
6.2.3 Market Forecast
6.3 Laser Therapy
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Region
7.1 North America
7.1.1 United States
7.1.1.1 Market Trends
7.1.1.2 Market Forecast
7.1.2 Canada
7.1.2.1 Market Trends
7.1.2.2 Market Forecast
7.2 Asia Pacific
7.2.1 China
7.2.1.1 Market Trends
7.2.1.2 Market Forecast
7.2.2 Japan
7.2.2.1 Market Trends
7.2.2.2 Market Forecast
7.2.3 India
7.2.3.1 Market Trends
7.2.3.2 Market Forecast
7.2.4 South Korea
7.2.4.1 Market Trends
7.2.4.2 Market Forecast
7.2.5 Australia
7.2.5.1 Market Trends
7.2.5.2 Market Forecast
7.2.6 Indonesia
7.2.6.1 Market Trends
7.2.6.2 Market Forecast
7.2.7 Others
7.2.7.1 Market Trends
7.2.7.2 Market Forecast
7.3 Europe
7.3.1 Germany
7.3.1.1 Market Trends
7.3.1.2 Market Forecast
7.3.2 France
7.3.2.1 Market Trends
7.3.2.2 Market Forecast
7.3.3 United Kingdom
7.3.3.1 Market Trends
7.3.3.2 Market Forecast
7.3.4 Italy
7.3.4.1 Market Trends
7.3.4.2 Market Forecast
7.3.5 Spain
7.3.5.1 Market Trends
7.3.5.2 Market Forecast
7.3.6 Russia
7.3.6.1 Market Trends
7.3.6.2 Market Forecast
7.3.7 Others
7.3.7.1 Market Trends
7.3.7.2 Market Forecast
7.4 Latin America
7.4.1 Brazil
7.4.1.1 Market Trends
7.4.1.2 Market Forecast
7.4.2 Mexico
7.4.2.1 Market Trends
7.4.2.2 Market Forecast
7.4.3 Others
7.4.3.1 Market Trends
7.4.3.2 Market Forecast
7.5 Middle East and Africa
7.5.1 Market Trends
7.5.2 Market Breakup by Country
7.5.3 Market Forecast
8 SWOT Analysis
8.1 Overview
8.2 Strengths
8.3 Weaknesses
8.4 Opportunities
8.5 Threats
9 Value Chain Analysis
10 Porters Five Forces Analysis
10.1 Overview
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Degree of Competition
10.5 Threat of New Entrants
10.6 Threat of Substitutes
11 Price Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Profiles of Key Players
12.3.1 Abbott Laboratories
12.3.1.1 Company Overview
12.3.1.2 Product Portfolio
12.3.1.3 Financials
12.3.1.4 SWOT Analysis
12.3.2 Allergan plc (AbbVie Inc.)
12.3.2.1 Company Overview
12.3.2.2 Product Portfolio
12.3.2.3 Financials
12.3.2.4 SWOT Analysis
12.3.3 Asahi Kasei Corporation
12.3.3.1 Company Overview
12.3.3.2 Product Portfolio
12.3.3.3 Financials
12.3.3.4 SWOT Analysis
12.3.4 Astellas Pharma Inc.
12.3.4.1 Company Overview
12.3.4.2 Product Portfolio
12.3.4.3 Financials
12.3.4.4 SWOT Analysis
12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
12.3.5.1 Company Overview
12.3.5.2 Product Portfolio
12.3.5.3 SWOT Analysis
12.3.6 Boston Scientific Corporation
12.3.6.1 Company Overview
12.3.6.2 Product Portfolio
12.3.6.3 Financials
12.3.6.4 SWOT Analysis
12.3.7 GlaxoSmithKline Plc
12.3.7.1 Company Overview
12.3.7.2 Product Portfolio
12.3.7.3 Financials
12.3.7.4 SWOT Analysis
12.3.8 Pfizer Inc.
12.3.8.1 Company Overview
12.3.8.2 Product Portfolio
12.3.8.3 Financials
12.3.8.4 SWOT Analysis
12.3.9 Sanofi S.A.
12.3.9.1 Company Overview
12.3.9.2 Product Portfolio
12.3.9.3 Financials
12.3.9.4 SWOT Analysis
12.3.10 Teva Pharmaceutical Industries Ltd.
12.3.10.1 Company Overview
12.3.10.2 Product Portfolio
12.3.10.3 Financials
12.3.10.4 SWOT Analysis
Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2021
Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2021
Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million US$), 2016 & 2021
Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter’s Five Forces Analysis
